ATRA

#3972
Atara Biotherapeutics, Inc. - Common Stock
9.2 0 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
9.20
9.20
Jahresspanne
3.92
19.14
Tagesänderung
-0.54%
Monatliche Änderung
+12.61%
6 month change
+76.58%
Jahresänderung
-37.63%
Vorheriger Schlusskurs
9.2 5
Open
9.2 0
Tief
9.2 0
Hoch
9.2 0
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Atara Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Atara Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Atara Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Atara Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Atara Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Atara Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Atara Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Atara Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Atara Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Atara Biotherapeutics, Inc. current report, Q1 FY2026
8-K

Atara Biotherapeutics, Inc. current report, Q1 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Atara Biotherapeutics, Inc. (Nasdaq: ATRA) on March 12, 2026. The filing reports a regulatory update regarding the company's lead product candidate, tabelecleucel (EBVALLO), an allogeneic T-cell immunotherapy for cancer and autoimmune diseases.

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory event and does not contain financial statements or results of operations.

Material Changes

  • Regulatory Meeting Scheduled: A Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) issued on January 9, 2026, regarding the Biologics License Application (BLA) for tabelecleucel.
  • Resubmission Strategy: The meeting will involve Atara's partner, Pierre Fabre Pharmaceuticals, to collaboratively address CRL points and enable a resubmission incorporating additional efficacy data collected since the original submission.

Guidance, Outlook, and Risks

Management Commentary: CEO AnhCo Nguyen expressed satisfaction with the FDA granting the Type A meeting and stated the company hopes to gain clarity on the path forward for BLA resubmission. Management anticipates providing a regulatory update in the second quarter of 2026.

Risks and Uncertainties: The filing highlights significant risks, including the uncertainty of clinical success, the FDA review process, and the company's ability to access capital. It also notes risks related to the sufficiency of cash resources, the timing of strategic reviews, and the potential failure to consummate strategic alternatives.

Investor Verification Checklist

  • Verify the specific outcomes and action items from the scheduled Type A FDA meeting once the second-quarter update is released.
  • Confirm the status of the Complete Response Letter (CRL) issued on January 9, 2026, and the specific deficiencies requiring additional efficacy data.
  • Review the company's most recent Form 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not provide financial figures.
  • Monitor announcements regarding the strategic review process and any potential strategic alternatives mentioned in the forward-looking statements.

Nachrichten